Atopic dermatitis (eczema) trials in Germany
22 of 31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Where
- Buxtehude, Dresden, Mainz, Osnabrueck, Potsdam, Tuebingen, Wuppertal
- Age
- 6 months to 11 years
- People
- 195 worldwide
- Run by
- LEO Pharma
See details and how to joinNCT06311682 · EU 2023-503630-44-00 - Phase 3Taking peopleA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Where
- Dresden, Muenster
- Age
- 2 years to 11 years
- People
- 450 worldwide
- Run by
- Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00 - Phase 2Taking peopleA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Where
- Friedrichshafen, Kiel, Luebeck, Muenster
- Age
- 18 years to 64 years
- People
- 165 worldwide
- Run by
- Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00 - No phaseNot yet taking people in GermanyLocalized Aeroallergen Exposure in Atopic Dermatitis
- Where
- Hanover
- Age
- 18 years to 65 years
- People
- 15
- Run by
- Fraunhofer-Institute of Toxicology and Experimental Medicine
See details and how to joinNCT07918586 - Phase 2Taking peopleA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Where
- Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Darmstadt, Dresden, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, München, Münster, Tübingen
- Age
- 18 years and over
- People
- 350 worldwide
- Run by
- Apogee Therapeutics, Inc.
See details and how to joinNCT07003425 - Phase 2Taking peopleA Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
- Where
- Bad Bentheim, Dresden, Frankfurt Am Main, Hamburg, Luebeck, Muenster
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- Apollo Therapeutics Limited
See details and how to join2026-525673-39-00 - Phase 3Taking peopleClinical study to compare two cutaneous creams with the active substance methylprednisolone aceponate 0.1% and one cutaneous cream without active substance for patients with atopic dermatitis
- Where
- Berlin, Bonn, Crimmitschau, Halle, Ibbenbüren, Kiel, Potsdam, Simmern, Vechta
- People
- 330
- Run by
- Dermapharm AG
See details and how to join2024-511390-30-00 - Phase 3Enrolling by invitationA Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Where
- Bad Bentheim, Darmstadt, Dresden, Frankfurt Am Main, Münster
- Age
- 6 months to 18 years
- People
- 338 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00 - Phase 3Taking peopleA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Where
- Aachen, Berlin, Bochum, Dresden, Hamburg, Heidelberg, Kiel, Leipzig, Muenster, Osnabrueck, Stuttgart, Wuppertal
- Age
- 12 years and over
- People
- 510 worldwide
- Run by
- Nektar Therapeutics
See details and how to joinNCT07690371 · EU 2025-524925-42-00 - Phase 3Not yet taking people in GermanyA Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
- Where
- Augsburg, Bad Bentheim, Berlin, Bochum, Cologne, Dresden, Duesseldorf, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Hamburg, Hanover, Heidelberg, Kiel, Luebeck, Mainz, Muenster, Munich, Regensburg, Rostock, Tuebingen
- Age
- 12 years and over
- People
- 230 worldwide
- Run by
- Almirall, S.A.
See details and how to joinNCT07873801 · EU 2025-525133-31-00 - Phase 2Not yet taking people in GermanyA study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
- Where
- Berlin, Frankfurt Am Main, Hamburg, Kiel, Luebeck, Muenster
- Age
- 18 years and over
- People
- 96 worldwide
- Run by
- Enveda Therapeutics Inc.
See details and how to join2026-526184-38-00 - Phase 2Taking peoplePlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Where
- Bad Bentheim, Dresden, Frankfurt Am Main, Goettingen, Hamburg, Heidelberg, Magdeburg, Mainz Bretzenheim, Muenster, Oldenburg, Osnabrueck
- Age
- 18 years to 100 years
- People
- 224 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00 - Phase 3Taking peopleA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Where
- Ahaus, Augsburg, Bad Bentheim, Berlin, Goettingen, Halle (Saale), Hamburg, Langenau, Merzig, Munich, Oldenburg, Regensburg, Tuebingen
- Age
- 12 years and over
- People
- 510 worldwide
- Run by
- Nektar Therapeutics
See details and how to joinNCT07711418 · EU 2025-525129-11-00 - Phase 1Taking peopleA first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.
- Where
- Bad Bentheim, Berlin, Dresden, Mainz
- Age
- 18 years to 64 years
- People
- 80 worldwide
- Run by
- Egle Therapeutics
See details and how to join2025-521658-40-00 - Phase 2Taking peopleA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Where
- Bad Bentheim, Dresden, Frankfurt, Hamburg, Lübeck, Münster, Witten
- Age
- 18 years to 65 years
- People
- 280 worldwide
- Run by
- Apollo Therapeutics Ltd
See details and how to joinNCT07599813 - Phase 2Taking peopleA Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
- Where
- Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Darmstadt, Dresden, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, Luebeck, Muenster, Munich, Tuebingen
- Age
- 18 years and over
- People
- 175 worldwide
- Run by
- Apogee Therapeutics Inc.
See details and how to join2024-519795-11-00 - Phase 3Taking peopleA Study of Lebrikizumab in Adults With Nummular Eczema
- Where
- Freiburg im Breisgau
- Age
- 18 years and over
- People
- 270
- Run by
- Almirall, S.A.
See details and how to joinNCT07542483 · EU 2025-522403-17-00 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Where
- Augsburg, Bad Bentheim, Berlin, Darmstadt, Dresden, Frankfurt Am Main, Hamburg, Luebeck, Muenster, Tuebingen
- Age
- 18 years to 74 years
- People
- 405 worldwide
- Run by
- Inmagene LLC
See details and how to joinNCT07037901 · EU 2024-520117-50-00 - No phaseTaking peopleEffect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
- Where
- Berlin, Düsseldorf, Frankfurt, Spandau, Wesel
- Age
- 1 day to 14 days
- People
- 400 worldwide
- Run by
- Société des Produits Nestlé (SPN)
See details and how to joinNCT06943469 - Phase 1Taking peopleA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
- Where
- Berlin, Frankfurt, Freiburg im Breisgau
- Age
- 18 years to 65 years
- People
- 149 worldwide
- Run by
- Sitryx Therapeutics Ltd
See details and how to joinNCT07558668 - Phase 2Taking peopleStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD
- Where
- Augsburg, Berlin, Dresden, Frankfurt Am Main, Luebeck, Muenster
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Corvus Pharmaceuticals, Inc.
See details and how to joinNCT07441395 · EU 2025-524384-20-00 - Phase 2Not yet taking people in GermanyA Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
- Where
- Berlin, Buxtehude, Hamburg
- Age
- 18 years and over
- People
- 50 worldwide
- Run by
- Aslan Pharmaceuticals Pte Ltd
See details and how to joinNCT05694884 · EU 2023-508329-28-00